IGMPI India

October 7, 2015

October 7, 2015

PAN Drugs receives warning letter from USFDA

USFDA has recently issued a warning letter to PAN drugs Vadodara based plant due to significant deviations from good manufacturing practices.

MHRA issues recall notice of Lacri-Lube eye ointment

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall notice to Allergen Limited. The recall notice relates to 5g and 3.5g pack sizes of

Another Import Ban for Polydrug Laboratories

USFDA (Food and Drug Administration) issues import ban for products manufactured by Polydrug Laboratories. It was issued on Sept. 11, 2015 for

Health Canada lifts its ban from two Apotex facilities in India

Health Canada has lifted its ban from Apotex two Indian facilities. Canada’s drug regulator reinspected the two plants in June and determined

33 drugs were found to be of not of standard quality during Surprise inspection

Recently Karnataka drug control department had conducted surprise inspections to pick up drug samples at random. The drug test labs have issued their result.

Vivimed Labs successfully completes USFDA inspection of its manufacturing facility

Vivimed Labs has recently successfully completed inspection of its API manufacturing facility in Spain. After the completion of inspection Vivimed said “the USFDA inspectors concluded

GMP News & Guidelines Archives:

VIEW HERE

Mithra Pharma working to make way for Indian companies in EU market

Mithra Pharma, which is a Belgium based drug Company, has plans to expand the domain of Indian drug companies. It has launched a platform, a campus that seems to open new doors and serve as a doorway for the Indian pharmaceutical companies into the European market.

As stated by the company, the campus aims to provide a regulatory and pioneering platform, which can help the Indian companies. This platform can facilitate the access of Indian companies and enable to increase their presence in the EU market.

The campus is strategically positioned taking into consideration the present challenges faced by the Indian pharmaceutical industry. Its infrastructure as well as a collaborative eco-system, will surely serve as a gateway for the Indian pharmaceutical companies to enter into the European market and increase their business there.